Jack Wallace
Stock Analyst at Guggenheim
(3.20)
# 1,107
Out of 4,911 analysts
19
Total ratings
57.89%
Success rate
243.44%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $290.41 | -14.26% | 4 | Oct 1, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $57.65 | -70.51% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $3.88 | +260.82% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $199.17 | +10.46% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $26.63 | +50.21% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $8.96 | +1,016.07% | 1 | Mar 15, 2023 | |
| PINC Premier | Initiates: Neutral | n/a | $21.16 | - | 1 | Apr 14, 2022 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $290.41
Upside: -14.26%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $57.65
Upside: -70.51%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $3.88
Upside: +260.82%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $199.17
Upside: +10.46%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $26.63
Upside: +50.21%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $8.96
Upside: +1,016.07%
Premier
Apr 14, 2022
Initiates: Neutral
Price Target: n/a
Current: $21.16
Upside: -